On January 23, 2026, Abbott’s Chairman and CEO, Robert Ford, acquired 18,800 additional common shares at approximately $107.13 each, bringing his total holdings to 216,203 shares. This transaction represents a significant insider vote of confidence, particularly as the company’s share price has dipped from its 52-week high of $141.23. Ford’s move signals that Abbott’s leadership believes the current valuation underrates the long-term potential of its diversified healthcare portfolio.

Despite pressure in its Nutrition business, Abbott’s Medical Devices division continues to drive performance, led by its Continuous Glucose Monitoring (CGM) franchise. In the latest quarter, CGM revenues grew by more than 20% year-over-year, offsetting a 5% decline in Nutrition sales caused by higher manufacturing costs and consumer price sensitivity. This resilience in medtech products has helped maintain the company’s overall gross margin near 59%, well above industry averages.

Management has projected a 7% increase in total sales and a 10% rise in earnings per share for fiscal 2025, underpinned by ongoing R&D investments and a normalization of the Nutrition segment. Abbott expects Nutrition revenues to return to growth in the second half of 2025 as cost-efficiency measures take effect and new product introductions gain traction. Meanwhile, diagnostics innovations, including expanded molecular and cardiac testing portfolios, are slated to contribute additional mid-single-digit revenue growth.

Abbott anticipates closing its acquisition of Exact Sciences in Q2 2026, a strategic move designed to add an oncology diagnostics vertical focused on early cancer detection. The deal is expected to complement Abbott’s existing diagnostics capabilities, potentially adding $500 million to $700 million in annual revenue by 2027. Leadership forecasts the integration will enhance operating leverage and support long-term margin expansion, positioning the company for accelerated top-line growth over the next five years.